686 related articles for article (PubMed ID: 15736111)
1. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
[TBL] [Abstract][Full Text] [Related]
2. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
Salen G; Shefer S; Tint GS
Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
[TBL] [Abstract][Full Text] [Related]
3. A novel pathway for biosynthesis of cholestanol with 7 alpha-hydroxylated C27-steroids as intermediates, and its importance for the accumulation of cholestanol in cerebrotendinous xanthomatosis.
Skrede S; Björkhem I; Buchmann MS; Hopen G; Fausa O
J Clin Invest; 1985 Feb; 75(2):448-55. PubMed ID: 3919058
[TBL] [Abstract][Full Text] [Related]
4. Noncholesterol sterols in bile and stones of patients with cholesterol and pigment stones.
Miettinen TE; Kesäniemi YA; Gylling H; Järvinen H; Silvennoinen E; Miettinen TA
Hepatology; 1996 Feb; 23(2):274-80. PubMed ID: 8591852
[TBL] [Abstract][Full Text] [Related]
5. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
Salen G; Berginer V; Shore V; Horak I; Horak E; Tint GS; Shefer S
N Engl J Med; 1987 May; 316(20):1233-8. PubMed ID: 3106810
[TBL] [Abstract][Full Text] [Related]
6. The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones.
Miettinen TE; Tarpila S; Gylling H
Hepatology; 1997 Mar; 25(3):514-8. PubMed ID: 9049189
[TBL] [Abstract][Full Text] [Related]
7. Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.
de Sain-van der Velden MG; Verrips A; Prinsen BH; de Barse M; Berger R; Visser G
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S387-93. PubMed ID: 18949577
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.
Mignarri A; Magni A; Del Puppo M; Gallus GN; Björkhem I; Federico A; Dotti MT
J Inherit Metab Dis; 2016 Jan; 39(1):75-83. PubMed ID: 26153518
[TBL] [Abstract][Full Text] [Related]
9. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.
Salen G; Grundy SM
J Clin Invest; 1973 Nov; 52(11):2822-35. PubMed ID: 4355999
[TBL] [Abstract][Full Text] [Related]
10. High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.
Kuriyama M; Fujiyama J; Kasama T; Osame M
J Lipid Res; 1991 Feb; 32(2):223-9. PubMed ID: 2066659
[TBL] [Abstract][Full Text] [Related]
11. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
Batta AK; Salen G; Tint GS
Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
[TBL] [Abstract][Full Text] [Related]
12. Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells.
Lindenthal B; Aldaghlas TA; Holleran AL; Sudhop T; Berthold HK; Von Bergmann K; Kelleher JK
Am J Physiol Endocrinol Metab; 2002 Jun; 282(6):E1222-30. PubMed ID: 12006351
[TBL] [Abstract][Full Text] [Related]
13. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis].
Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M
Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315
[TBL] [Abstract][Full Text] [Related]
14. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
Kallien G; Lange K; Stange EF; Scheibner J
Hepatology; 1999 Jul; 30(1):14-20. PubMed ID: 10385633
[TBL] [Abstract][Full Text] [Related]
15. Applicability of non-cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men.
Nissinen MJ; Miettinen TE; Gylling H; Miettinen TA
Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):308-16. PubMed ID: 19695854
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
Kuriyama M; Tokimura Y; Fujiyama J; Utatsu Y; Osame M
J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
[TBL] [Abstract][Full Text] [Related]
18. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.
Miettinen TA; Gylling H; Lindbohm N; Miettinen TE; Rajaratnam RA; Relas H;
J Lab Clin Med; 2003 Feb; 141(2):131-7. PubMed ID: 12577049
[TBL] [Abstract][Full Text] [Related]
19. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
Dotti MT; Lütjohann D; von Bergmann K; Federico A
Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
[TBL] [Abstract][Full Text] [Related]
20. [Cerebrotendinous xanthomatosis].
Berginer VM
Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(4):13-22. PubMed ID: 1333699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
